CRM Becomes First Southeast Asia Research Organisation to Join IQVIA’s Global EPON

Seating L-R: Mr. Teck Kwang Koh, General Manager at IQVIA Malaysia and Dr. Akhmal Yusof. Standing L-R: Dr Voon Pei Jye, Mr. Desmond Dorairajoo, Dato’ Dr. Goh Pik Pin and Mr. David Horsburgh.

KUALA LUMPUR, 28 November 2018 – Clinical Research Malaysia (CRM) today signed a memorandum of understanding (MoU) to establish a strategic alliance with IQVIA’s global Early Phase Oncology Network (EPON).

The agreement makes Clinical Research Centre at Sarawak General Hospital the first in Southeast Asia to be part of IQVIA’s prestigious network of globally qualified Phase I oncology sites. CRM, established by the Malaysian Ministry of Health in 2012, exists to advance Malaysia’s ability to contribute to global health solutions. IQVIA is a leading global provider of contract research services, advanced analytics and technology solutions to the life-sciences industry.

“This agreement is a major step forward for the country of Malaysia to provide advanced Phase I studies for investigational cancer therapies,” said CRM Chief Executive Officer Dr Akhmal Yusof.  “Advances in genomics offer new hope for targeted oncology products. Through this agreement, Sarawak General Hospital will join IQVIA’s global Early Phase Oncology Network, which is designed to provide fast, high-quality Phase I oncology studies to biopharmaceutical companies.”

IQVIA Asia Pacific President Anand Tharmaratnam said: “This agreement builds upon our long relationship with Clinical Research Malaysia as an IQVIA Prime Site.  Adding Sarawak General Hospital’s research centre gives biopharma companies, for the first time, a Southeast Asia location as part of IQVIA’s global network of high quality early phase oncology research sites.  This is a significant step forward in our joint mission to accelerate the development of targeted oncology therapies in Malaysia and Asia for the benefit of patients worldwide.”

IQVIA has been conducting oncology early clinical research in Asia Pacific for more than two decades.  The IQVIA EPON-Clinical Research Malaysia strategic alliance is designed to streamline study startup, enhance consistency, and deliver high-quality results faster.

This collaboration is intended significantly improve the quality of early phase oncology trials in Malaysia by having innovative investigational therapies as an option for patients. This aligns with the Phase I Realization Project (P1RP) that was launched by CRM in 2016 which is focused in enhancing Malaysia’s early phase clinical research capacity and building a more attractive early phase clinical research ecosystem.

The MoU is signed between Dr Akhmal Yusof and on behalf of IQVIA, Mr. Teck Kwang Koh, General Manager at IQVIA Malaysia. The signing of the MoU was witnessed by the Director of Network of Clinical Research Centre, YBhg. Dato’ Dr. Goh Pik Pin, Dr Voon Pei Jye of Sarawak General Hospital, Mr. Desmond Dorairajoo, Head of Academic Research Group Asia-Pacific IQVIA and Mr. David Horsburgh, Asia Strategy Lead, Academic Research Group Asia-Pacific IQVIA.

About CRM

Established by the Malaysian Ministry of Health in 2012, CRM exists to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to-end clinical research support for quality studies. CRM’s innate understanding of the local clinical research landscape with the international standards of operations coupled with fundamental backing of the government ministries provide us an incomparable advantage to work with partners from the nascent stages of development to materialisation of the end product, in order to deliver better treatment and high skilled job opportunities.



IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.To learn more, visit


Hospital Sibu Top 5 Recruiter Globally for Respire RSV Study

Dr. Toh Teck Hock and his clinical research team has set another milestone in Hospital Sibu, Sarawak for the Respire RSV study recently as they are the world’s top 5 recruiter in the Respire RSV study.

“Although Sibu has a number of queries (which is normal), but our Study Coordinators (SC) were fast to resolve those queries. To me it shows the “Quality” work our SC has done (Of course, the Co-I has to be good too)” – Dr Toh Teck Hock, Head of Clinical Research Centre, Hospital Sibu.

We would like to congratulate Dr. Toh and his team in Hospital Sibu for the great achievement!

Check out CRM Bulletin Issue 15 as we featured Dr. Toh recently, to find out more about Dr Toh visit…/

Read more contents from CRM Bulletin Issue 15. Download here!

Japanese Pharmaceutical Companies Show Interest to Conduct Clinical Trials in Malaysia

TOKYO, 6 November 2018 – Clinical Research Malaysia (CRM) hold a half-day seminar that targets Japanese pharmaceutical and medical device companies interested in conducting clinical trials in the Asian region. This is the first time for CRM to deliver a clinical trial seminar focusing on its home country in Japan.

Read more

Dr Akhmal Yusof – CEO, Clinical Research Malaysia (CRM) – PHARMA BOARDROOM

Dr Akhmal Yusof, CEO of CRM sheds light on the capacity for all stages of clinical research in Malaysia. He discusses the importance of human resources for the country’s research future and explains what makes Malaysia such a worthwhile location to invest in international clinical research.

Read more

2018 People’s Choice Winner Roshaida Abdul Wahab, University College Dublin The Truth, the Whole Truth and Nothing but The Truth

Congratulations to Roshaida Abdul Wahab from University College Dublin as she was selected as the People’s Choice Winner for the U21 Three Minute Thesis (3MT®) Competition recently.

Read more

Evolution of Clinical Trial Agreement Review in Malaysia Through CRM

To regulate the conduct, relationships, responsibilities, and obligations of the parties involved in the clinical trial, the Clinical Trial Agreement (CTA) must be in place. The parties in a CTA are not usually limited to sponsors or contract research organizations (CROs), but also include institutions and principal investigators. The Malaysian Guideline for Good Clinical Practice, has defined the CTA as“A written, dated, and signed agreement between two or more involved parties that sets out any arrangements on delegation and distribution of tasks and obligations and, if appropriate, on financial matters. The protocol may serve as the basis of a contract.”(1)

Read more

Embracing Digital Health

L-R: YBrs. Dr. Kalaiarasu M. Periasamy, Deputy Director, National Clinical Research Centre, Y.Bhg. Datuk Dr. Shahnaz Murad, Deputy General-Director of Health Malaysia (Research & Technical Support), YB. Dr. Lee Boon Chye, Deputy Minister of Health, YBrs. Dr. Akhmal Yusof, CEO of Clinical Research Malaysia, YBhg. Dato’ Dr. Goh Pik Pin, Director National Clinical Research Malaysia

KUALA LUMPUR, 24 September 2018 – The 12thNational Conference for Clinical Research (NCCR) brought together medical experts and researchers under one platform to understand the way digital technology can impact the Malaysian healthcare delivery system, thus potentially improving patient outcomes.

Read more

Malaysia conducts clinical trials to improve patient survival

PUTRAJAYA, Sept 5 (Bernama) – Around 850 oncology and therapeutics clinical trials are conducted in Malaysia per year to improve patient survival, said Health Ministry (research and technical support) deputy director-general, Datuk Dr Shahnaz Murad.

Read more